Re: Two phase 2 trials of the novel akt inhibitor perifosine in patients with advanced renal cell carcinoma after progression on vascular endothelial growth factor targeted therapy: Editorial comment

Samir S. Taneja

Research output: Contribution to journal › Comment/debate › peer-review

Fingerprint

Dive into the research topics of 'Re: Two phase 2 trials of the novel akt inhibitor perifosine in patients with advanced renal cell carcinoma after progression on vascular endothelial growth factor targeted therapy: Editorial comment'. Together they form a unique fingerprint.